vs
Side-by-side financial comparison of CASTLE BIOSCIENCES INC (CSTL) and IMAX CORP (IMAX). Click either name above to swap in a different company.
IMAX CORP is the larger business by last-quarter revenue ($125.2M vs $87.0M, roughly 1.4× CASTLE BIOSCIENCES INC). On growth, IMAX CORP posted the faster year-over-year revenue change (35.1% vs 0.8%). IMAX CORP produced more free cash flow last quarter ($28.0M vs $19.7M). Over the past eight quarters, IMAX CORP's revenue compounded faster (25.8% CAGR vs 9.2%).
Castle Biosciences Inc. is a commercial-stage diagnostic firm that develops and markets proprietary, clinically actionable tests for dermatological conditions such as melanoma and other skin cancers, plus rare diseases. It operates mainly in the U.S. healthcare market, focusing on segments with high unmet need for more accurate diagnostics to guide treatment choices.
IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.
CSTL vs IMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $87.0M | $125.2M |
| Net Profit | — | $637.0K |
| Gross Margin | 79.0% | 57.6% |
| Operating Margin | -4.4% | 19.3% |
| Net Margin | — | 0.5% |
| Revenue YoY | 0.8% | 35.1% |
| Net Profit YoY | — | -88.0% |
| EPS (diluted) | $-0.06 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $87.0M | $125.2M | ||
| Q3 25 | $83.0M | $106.7M | ||
| Q2 25 | $86.2M | $91.7M | ||
| Q1 25 | $88.0M | $86.7M | ||
| Q4 24 | $86.3M | $92.7M | ||
| Q3 24 | $85.8M | $91.5M | ||
| Q2 24 | $87.0M | $89.0M | ||
| Q1 24 | $73.0M | $79.1M |
| Q4 25 | — | $637.0K | ||
| Q3 25 | $-501.0K | $20.7M | ||
| Q2 25 | $4.5M | $11.3M | ||
| Q1 25 | $-25.8M | $2.3M | ||
| Q4 24 | — | $5.3M | ||
| Q3 24 | $2.3M | $13.9M | ||
| Q2 24 | $8.9M | $3.6M | ||
| Q1 24 | $-2.5M | $3.3M |
| Q4 25 | 79.0% | 57.6% | ||
| Q3 25 | 77.5% | 63.1% | ||
| Q2 25 | 79.5% | 58.5% | ||
| Q1 25 | 81.4% | 61.4% | ||
| Q4 24 | 81.3% | 52.2% | ||
| Q3 24 | 81.8% | 55.8% | ||
| Q2 24 | 83.3% | 49.4% | ||
| Q1 24 | 81.0% | 59.3% |
| Q4 25 | -4.4% | 19.3% | ||
| Q3 25 | -8.2% | 27.2% | ||
| Q2 25 | -4.9% | 15.6% | ||
| Q1 25 | -31.7% | 19.3% | ||
| Q4 24 | 4.7% | 10.3% | ||
| Q3 24 | 5.9% | 21.2% | ||
| Q2 24 | 5.8% | 3.2% | ||
| Q1 24 | -7.5% | 15.3% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | -0.6% | 19.4% | ||
| Q2 25 | 5.2% | 12.3% | ||
| Q1 25 | -29.4% | 2.7% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | 2.6% | 15.2% | ||
| Q2 24 | 10.3% | 4.0% | ||
| Q1 24 | -3.5% | 4.1% |
| Q4 25 | $-0.06 | $0.02 | ||
| Q3 25 | $-0.02 | $0.37 | ||
| Q2 25 | $0.15 | $0.20 | ||
| Q1 25 | $-0.90 | $0.04 | ||
| Q4 24 | $0.32 | $0.09 | ||
| Q3 24 | $0.08 | $0.26 | ||
| Q2 24 | $0.31 | $0.07 | ||
| Q1 24 | $-0.09 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $299.5M | $151.2M |
| Total DebtLower is stronger | $10.1M | — |
| Stockholders' EquityBook value | $470.9M | $337.9M |
| Total Assets | $578.6M | $894.0M |
| Debt / EquityLower = less leverage | 0.02× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $299.5M | $151.2M | ||
| Q3 25 | $287.5M | $143.1M | ||
| Q2 25 | $275.9M | $109.3M | ||
| Q1 25 | $275.2M | $97.1M | ||
| Q4 24 | $293.1M | $100.6M | ||
| Q3 24 | $95.0M | $104.5M | ||
| Q2 24 | $85.6M | $91.6M | ||
| Q1 24 | $82.9M | $81.0M |
| Q4 25 | $10.1M | — | ||
| Q3 25 | $10.0M | — | ||
| Q2 25 | $10.0M | — | ||
| Q1 25 | $10.0M | — | ||
| Q4 24 | $10.0M | — | ||
| Q3 24 | $10.0M | — | ||
| Q2 24 | $10.0M | — | ||
| Q1 24 | $10.0M | — |
| Q4 25 | $470.9M | $337.9M | ||
| Q3 25 | $467.0M | $349.5M | ||
| Q2 25 | $455.4M | $320.4M | ||
| Q1 25 | $440.3M | $299.5M | ||
| Q4 24 | $455.8M | $299.5M | ||
| Q3 24 | $441.1M | $289.4M | ||
| Q2 24 | $423.9M | $267.2M | ||
| Q1 24 | $402.5M | $258.8M |
| Q4 25 | $578.6M | $894.0M | ||
| Q3 25 | $562.8M | $889.6M | ||
| Q2 25 | $544.7M | $868.6M | ||
| Q1 25 | $501.7M | $848.3M | ||
| Q4 24 | $531.2M | $830.4M | ||
| Q3 24 | $514.6M | $847.6M | ||
| Q2 24 | $487.3M | $827.4M | ||
| Q1 24 | $458.5M | $824.1M |
| Q4 25 | 0.02× | — | ||
| Q3 25 | 0.02× | — | ||
| Q2 25 | 0.02× | — | ||
| Q1 25 | 0.02× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | 0.02× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $26.9M | $29.4M |
| Free Cash FlowOCF − Capex | $19.7M | $28.0M |
| FCF MarginFCF / Revenue | 22.7% | 22.3% |
| Capex IntensityCapex / Revenue | 8.3% | 1.1% |
| Cash ConversionOCF / Net Profit | — | 46.11× |
| TTM Free Cash FlowTrailing 4 quarters | $28.3M | $118.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $26.9M | $29.4M | ||
| Q3 25 | $22.6M | $67.5M | ||
| Q2 25 | $20.8M | $23.2M | ||
| Q1 25 | $-6.0M | $7.0M | ||
| Q4 24 | $24.4M | $11.5M | ||
| Q3 24 | $23.3M | $35.3M | ||
| Q2 24 | $24.0M | $35.0M | ||
| Q1 24 | $-6.8M | $-11.0M |
| Q4 25 | $19.7M | $28.0M | ||
| Q3 25 | $7.8M | $64.8M | ||
| Q2 25 | $11.6M | $20.9M | ||
| Q1 25 | $-10.8M | $5.3M | ||
| Q4 24 | $16.8M | $6.9M | ||
| Q3 24 | $17.0M | $34.2M | ||
| Q2 24 | $18.8M | $33.5M | ||
| Q1 24 | $-16.0M | $-12.1M |
| Q4 25 | 22.7% | 22.3% | ||
| Q3 25 | 9.4% | 60.7% | ||
| Q2 25 | 13.4% | 22.8% | ||
| Q1 25 | -12.2% | 6.1% | ||
| Q4 24 | 19.5% | 7.4% | ||
| Q3 24 | 19.8% | 37.3% | ||
| Q2 24 | 21.6% | 37.6% | ||
| Q1 24 | -21.9% | -15.3% |
| Q4 25 | 8.3% | 1.1% | ||
| Q3 25 | 17.9% | 2.6% | ||
| Q2 25 | 10.7% | 2.6% | ||
| Q1 25 | 5.4% | 1.9% | ||
| Q4 24 | 8.8% | 5.0% | ||
| Q3 24 | 7.4% | 1.2% | ||
| Q2 24 | 6.0% | 1.8% | ||
| Q1 24 | 12.5% | 1.4% |
| Q4 25 | — | 46.11× | ||
| Q3 25 | — | 3.27× | ||
| Q2 25 | 4.60× | 2.06× | ||
| Q1 25 | — | 2.99× | ||
| Q4 24 | — | 2.16× | ||
| Q3 24 | 10.29× | 2.54× | ||
| Q2 24 | 2.69× | 9.78× | ||
| Q1 24 | — | -3.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSTL
| Dermatologic | $48.6M | 56% |
| Non Dermatologic | $38.4M | 44% |
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
